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Abstract
Background: Respiratory syncytial virus (RSV) is the major cause of lower respiratory tract infection in infants. The rate of
decay of RSV-specific maternal antibodies (RSV-matAb), the factors affecting cord blood levels, and the relationship
between these levels and protection from infection are poorly defined.
Methods: A birth cohort (n = 635) in rural Kenya, was studied intensively to monitor infections and describe age-related
serological characteristics. RSV specific IgG antibody (Ab) in serum was measured by the enzyme linked immunosorbent
assay (ELISA) in cord blood, consecutive samples taken 3 monthly, and in paired acute and convalescent samples. A linear
regression model was used to calculate the rate of RSV-matAb decline. The effect of risk factors on cord blood titres was
investigated.
Results: The half-life of matAb in the Kenyan cohort was calculated to be 79 days (95% confidence limits (CL): 76–81 days).
Ninety seven percent of infants were born with RSV-matAb. Infants who subsequently experienced an infection in early life
had significantly lower cord titres of anti-RSV Ab in comparison to infants who did not have any incident infection in the first
6 months (P = 0.011). RSV infections were shown to have no effect on the rate of decay of RSV-matAb.
Conclusion: Maternal-specific RSV Ab decline rapidly following birth. However, we provide evidence of protection against
severe disease by RSV-matAb during the first 6–7 months. This suggests that boosting maternal-specific Ab by RSV
vaccination may be a useful strategy to consider.
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Introduction
Respiratory syncytial virus (RSV) is the single most important
viral cause of lower respiratory tract infection (LRTI) during
infancy and early childhood worldwide [1,2,3]. The role of RSV
antibodies (Ab) in infant protection in the developing world, where
the epidemiology of RSV and related infections may differ from
that in developed regions, is only now being evaluated [2,4]. There
is a paucity of information on the role of RSV-specific maternal
antibodies (RSV-matAb).
The incidence of bronchiolitis in infants below 2 months of age
has been observed to be markedly lower than in older children
[5,6,7,8]. The incidence of pneumonia has also been documented
as being lower but less strikingly so. Additionally, pneumonia is
uncommon and bronchiolitis very rare in infants under 3 weeks of
age [9,10]. Within this context therefore, RSV-matAb play an
important role in protection against severe RSV-associated illness.
While there is evidence that RSV-matAb are likely to be important
in protection against RSV disease, severe disease is noted in
children under 6 months of age, paradoxically at a time when
RSV-matAb are frequently identified, but may be waning.
The importance of RSV-matAb protection against disease is
further illustrated by the fact that infants born during or just prior
to the RSV season, during the time when titers are likely to be the
lowest in the mothers, have been described as being at maximum
risk of admission to hospitals with RSV infection in the ensuing
RSV season [11]. Further studies have shown the relationship of
neutralizing Ab titres to RSV with severity of LRTI, noting an
inverse correlation between the two measures [2,8,12,13,14,15].
These observations underscore the importance of high matAb
concentration in reducing the risk of severe disease in early months
of life.
It has also been demonstrated that the administration of
prophylactic intravenous immunoglobulin enriched for high levels
of RSV neutralizing Ab (RSV Immune Globulin or RSV-IGIV) or
humanized monoclonal Ab against F protein are associated with
reduction of RSV-associated disease [12,16,17]. The use of
maternal immunization to augment this protection in young
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infants against disease shows promise and thus lends itself to
further consideration [18]. It is plausible that RSV-associated
disease under 6 months of age is due to low RSV-matAb levels
and/or RSV-matAb not being fully protective (for example, due to
strain-specificity). The latter have also been said to interfere with
vaccine efficacy and may eventually lead to vaccine failure [19]
especially with regards to early paediatric live vaccines.
To document the levels and duration of RSV-matAb, and to
understand factors which may affect these levels, we undertook to
characterize the levels of RSV-matAb and their decay rate in a
birth cohort from rural Kenya. The effects of risk factors on
matAb decay and cord titres were investigated using multiple
linear regression analysis. This work is preliminary to further
analysis of the relationship between matAb level and protection.
Materials and Methods
Ethics Statement
The research project was one of several studies nested within a
birth cohort study of RSV [20,21] in Kilifi District, which was
reviewed and passed as ethically acceptable by the Kenya Medical
Research Institute/National Ethic Review Committee and Coven-
try Research Ethics Committee, UK.Written informed consent was
obtained from each caregiver of every child enrolled in the study.
Study Population and Samples
The study was carried out in the District of Kilifi an area
covering 4779 km2 in rural coastal Kenya. The population of
around 500,000, predominantly subsistence farmers, has a growth
rate of 3.1% per annum, with 18%,5 years in age [22]. The
District hospital is located within Kilifi town, located 60 km north
of Kenya’s main port city of Mombasa.
Newly delivered babies at Kilifi District Hospital (KDH) or
infants attending the Maternal Child Health Clinic at KDH within
the first 2 weeks of life were recruited. About 300 children each
were recruited in 2 phases to the birth cohort, between February –
May 2002, and December 2002 – May 2003 respectively, and
were intensively monitored for acute respiratory infections (ARI).
The surveillance procedure of infants, including the details of
collection, cold chain to the laboratory and sample processing has
been extensively described previously [20,21]. Briefly, active
household surveillance for ARI was weekly during RSV epidemics
and monthly otherwise. Passive surveillance was carried out
principally through parental referral to outpatient research clinic
(Monday- Friday, 8 A.M- 5 P.M.) at KDH [21]. Passive referral
was encouraged for a child with any ARI symptoms. At each
contact, a nasal washing (NW) was collected if the child had any
respiratory symptoms. Blood samples, which included cord blood
and repeated blood samples taken at approximately 3 monthly
intervals were collected from each child; if a child experienced a
positive RSV event identified on screening NWs using the indirect
immunofluorescence antigen test (IFAT) (Light Diagnostics DFA
Screen, Chemicon International Inc., Temecula, CA), an acute
blood sample was collected as well as a convalescent sample 1
month later (See Figure 1 for schema of sample collection regime
in relation to age and epidemics).
Enzyme Linked Immunosorbent Assay (ELISA) Procedure
The enzyme-linked immunosorbent assay (ELISA) was based on
that of Wilson et al. [23]. RSV laboratory strain A2 was used to infect
HEp-2 cells. Following harvesting of lysate from both mock-infected
and RSV-A2-infected cells, the resulting supernatant was sonicated
(Sonics & Materials, Inc., Newton, CT) at 70% amplitude, 361 min
cycles with 1s pulse and 1s pause. Lysates were then vortexed
thoroughly prior to coating triplicate wells of 96-well Nunc-
ImmunoTM MaxiSorpTM plates (Fisher Scientific, Leicestershire,
UK) with 25 mL of a 1/32 dilution in phosphate buffer saline (PBS)
coating buffer of either RSV-A2-infected or mock-infected cell
lysates. Plates were dried overnight at 37uC in a rotating incubator.
These were then blocked with 200 mL/well of 5% driedmilk (Marvel)
in PBS and incubated for 1 hr at 37uC. Serum samples and controls
were diluted 1/100 in dried milk in PBS. All plates included serial
dilutions (1/50 to 1/1600) of a high titre local standard of pooled
adult sera used to generate a standard curve. This was given an
arbitrary unit (AU) value of 1000. Resultant test OD readings were
adjusted for mock antigen results. All test sera were then calibrated
using the standard curve and Ab reported as AU. The rest of the
assay was carried out as previously described [23].
Indirect immunofluorescence antigen test (IFAT)
This was carried out as previously described by Nokes et al. [21].
Definitions
An ‘IFAT confirmed’ serological response was defined as a
seroconversion or two-fold rising titre (0.3 log10AU) occurring
between acute and convalescent sera collected approximately 1
month apart on identification of IFAT positive NWs. An ‘ELISA
confirmed’ serological responses was defined as a 2-fold specific Ab
increase occurring between two samples collected 3 months apart
(without antigen confirmation by IFAT).
Data Analysis
All data analysis was undertaken using Stata 9.0TM. As Ab
measurements were highly positively skewed, all analyses were
carried out after the transformation of anti-RSV Ab serological
levels from standardized AU to log10 AU. The determination of an
appropriate cut-off delineating positive and negative sera was
assessed using a frequency distribution of Ab titres for all sera
screened. Seroconversion was defined as a 2-fold (0.3 log AU) or
greater rise in titres between 2 samples collected consecutively.
Passively acquired IgG is subject to an exponential decay rate [24],
hence the rate of RSV-specific matAb decay, a, was estimated
using the linear regression on log Ab concentrations, assuming
y að Þ~yoe{aa
where yo is the mean Ab level at birth and y(a) the mean Ab titre at
a given age, a.
Accounting for clustering due to multiple measurements per
child was undertaken using a random effects model.
Results
Descriptive Analysis of study population
Six hundred and thirty five infants were recruited to the birth
cohort and followed to approximately 3 years of age. A total of 521
cord bloods, 2,777 three monthly serum samples, 295 acute and
272 convalescent blood samples were collected (Figure 1). The
male: female ratio was approximately 1:1, with the majority of
infants weighing between 2–3 kg (47.7%) or 3–4 kg (46.1%) at
birth. The majority were either 1st (28.7%), 2nd (21.3%), 3rd (15%)
or 4th (14.8%) born.
Frequency distribution and prevalence of RSV-specific
antibody titres
The RSV-specific Ab titres during the first 6 months are shown in
Figure 2. A cut-off between seropositive and seronegative sera fell
RSV-matIg in Kenyan Infants
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within the range of 1.5–1.8 log AU as noted from the bimodal
frequency distribution of Ab titres for all sera and by age group
(Figure 3). The mean Ab titre for seropositive infants at the cut-off of
1.5 log AU (also the lower limit of sensitivity of the ELISA - data not
shown) was then constructed and indicated an average low titer
point at about 4–5 months of age, with a low plateau maintained
from about 4–10 months of age. A similar profile was noted when
using the 1.8 log AU cut-off (this is the level at which approximately
50% of population was seronegative; profile not shown).
We also compared the proportion of samples above the 1.5 log
cut-off for positivity during 0–6 months of life (Figure 4). At the
cut-off of 1.5 log AU, 97% of infant displayed matAb.
Seroprevalence gradually declined with age to around 50% at
ages 4-,5 and 5-,6. The effect of raising the cut-off for
seropositivity between logAU 1.5 and 3.5 is shown in Figure 4.
Seroprevalence is around 10% of children by age 4.5, 2.5, 1.5 and
0 months for progressively higher cut-off levels of 2, 2.5, 3, and
3.5, respectively.
Analysis of the antibody response model
From the Ab titre distribution curve, it was noted that RSV-
specific matAb declined log linearly over the first six months of life.
A simple linear regression model was fitted through all the data
points for children less than 6 months of age irrespective of
whether they experienced any infection or not (Figure 5) and the
rate of decay calculated. For Ab values,1.5 log AU these were
corrected to 1.5 log AU, and the rate comprising these values
compared to the rate when the latter were not corrected. No
significant difference was noted. To calculate the ‘pristine’ rate of
Figure 1. Schema of sample collection regime for Kilifi cohort. 635 children were recruited to a birth cohort in 2 phases (February- May 2002,
and December 2002- May 2003). Cord bloods (circles), together with sera every 3 months (triangles) were collected. Any antigen positive nasal
washing detected by IFAT collected upon each ARI episode, prompted collection of paired acute (asterix) and convalescent (squares) phase sera. The
first 2 epidemics experienced by the cohort are indicated by the black bars.
doi:10.1371/journal.pone.0008088.g001
Figure 2. The level of RSV-specific matAb by age (months) in a
birth cohort, Kilifi Kenya. Box plot of log10AU Ab levels for age
categories defined as 0 months (cord), 0.5 (.0-,1), 1.5 (1-,2), 2.5 (2-
,3), 3.5 (3-,4), 4.5 (4-,5) and 5.5 (5-,6) months. The red horizontal
line defines the cut-off for seropositivity of 1.5 log10AU.
doi:10.1371/journal.pone.0008088.g002
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decay in the seropositive population, infants who experienced at
least 1 infection, defined as either an ELISA-confirmed or IFAT-
confirmed serological increase, were excluded. This gave 2
population groups; non-infected (851 samples) and infected (372
samples). A random effects mixed model to account for the
multiple measurements per child was investigated and compared
to the simpler linear model. No significant difference was found
between the predictors used in these two models.
The ‘pristine’ half-life (T1/2) in days of RSV-specific matAb for
the seropositive population was 79 days (95% CL: 76–81 days),
whilst the mean ‘pristine’ duration or length of time that an infant
remained above the cut-off (in days) was 112 (95% CL: 107–118).
No significant differences were noted for either T1/2 or mean
duration of RSV-matAb when the whole population (infected
group included) was similarly analyzed.
Examination of possible risk factors affecting cord blood
levels and rate of decay
The effects of risk factors on cord blood levels of both infected
and non-infected populations were evaluated initially using a two-
sample t-test followed by a multiple linear regression model. With
regards to matAb titres, after controlling for birth weight level,
Figure 3. Frequency distribution of antibody titres (log10 AU) by age class (months). Cut-off between seropositive and seronegative is
shown by red lines and lies between 1.5–1.8 (log10AU).
doi:10.1371/journal.pone.0008088.g003
Figure 4. Age-seroprevalence profile at various cut-off levels of seropositivity. The assay cut-off value of seropositivity is 1.5.
doi:10.1371/journal.pone.0008088.g004
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birth order levels and being born in or out of an epidemic, using a
multiple linear regression model, a univariate analysis was initially
performed, and subsequently all variables, irrespective of signifi-
cance level at univariate analysis, combined. The matAb titres for
the infected groups remained significantly lower (P= 0.011) when
compared to the non-infected groups (3.02 log AU versus 2.81 log
AU; t = 2.32, df = 91.46, P= 0.011; 1 tail; an ELISA-confirmed
serological response at the at the 2-fold seroconversion cut-off
level).
It was noted that only cord blood levels (P,0.001) affected the
rate of decay of the two population subgroups (non-infected and
infected children), the remaining risk factors having no effect. With
reference to the rate of decay or differences in gradient of matAb
decline between these two population subgroups however, no
differences (20.009 versus 20.007, t =21.47, df = 109.39,
P= 0.145; 2 tail) were identified.
Discussion
RSV specific matAb and infection were investigated in a birth
cohort comprising 635 children in Kilifi District. The distribution,
duration and risk factors of RSV maternally-derived immunity
over the 1st six months of life were explored.
At the cut-off point for seropositivity of 1.5 log AU (ascertained
from the bimodal distribution of the assay results), maternal
transfer was deemed to be efficient as approximately 97% of
infants displayed RSV-specific matAb at birth. By 6–7 months
however, 50% infants were noted to be still seropositive. This is in
contrast to earlier studies [6,7,25] with the exception of the study
by Ebihara et al. [26], in which seroprevalence levels were seen to
reach a nadir by 6 months of life, and seroprevalence varied from
between 2–16% when carried out by the ELISA, and 21% by both
the G- and F-specific (RSV surface glycoproteins) competition
ELISA. In the study by Ebihara and colleagues [26], a similar level
of prevalence of 48% was observed.
Increasing the cut-off levels for seropositivity from 1.5 to 1.8 log
AU and above, resulted in a more rapid decline in seropositivity
and a minimum Ab level being attained by 6 months, as previously
described [6,7,25]. There is little data to indicate what level of
systemic anti-RSV Ab provides adequate transudate across the
respiratory mucosa to confer protection from infection. The
relationship between cut-off level and rate of decay in seroprev-
alence (Figure 4) provides possible scenarios for the rate of decay of
actual protective titres of RSV antibody which requires clarifica-
tion.
It should be borne in mind that the measurement of ELISA
binding titres using a crude extract is an indirect measure of
functional Ab. It would have been more suitable to measure
neutralizing Ab titres to get a direct measurement of functional Ab
following infection and in the presence of matAb. Furthermore,
the use of A2 rather than the currently circulating strain in the
assay procedure could have led to an under-estimation of
seroconversion due to poor cross-reactivity [4].
Over the first 6 months, the ‘pristine’ T1/2 of RSV-specific
matAb in the population without both serologic evidence and/or
IFAT-positive indication of infection was estimated as 79 days
(95% CL: 76–81) and matAb had an average duration of 112 days
(95% CL: 107–118). This rate of decay is shorter than that
observed by Cox et al. [7], Ward et al. [15] and Hacimustafaoglu et
al. [25]. These authors calculated rates that varied from between
91–100 days, although it is not clear as to whether the authors
included or excluded seronegative individuals with infections in
their calculations. This rate for RSV- matAb decay for the Kilifi
population however, was longer than that for measles, mumps and
rubella [24,27], and human parainfluenza type 3 [28], which vary
from 35–40 and 51 days respectively. Again, however, it is
important to recognise the likely difference between the protective
potential of matAb to these systemic infections as opposed to
protection against RSV at the respiratory mucosa.
Our study suggests that the rate of matAb decay does not differ
between the wider population that also included those who had
infections compared to the non-infected population. This implies
that RSV infections below 6 months of age have no significant
effect on the rate of RSV-specific matAb decay. In other words,
the presence of matAb has a masking effect on infections under 6
months of life, and thus seroconversions in this age group will not
be easily identified. Risk factors affecting both RSV cord titres and
RSV matAb decline were analyzed using both the 2-sample t-test
and multiple linear regression analysis. With respect to cord blood
titres, children who went on to experience an infection within 6
months of age were observed to have consistently significantly
lower titres in comparison to the children who did not experience
infection within this period. This is in agreement with the study by
Stensballe and others [29], who found a clear correlation with
decrease in mean cord blood RSV Ab titres and steep increase in
the number of RSV hospitalizations in infants younger than 6
months of age. This therefore implies that matAb are protective as
earlier described [2,12,14], which has implications for the
development of a maternal vaccine [2,25].
The relatively short half-life of RSV matAb of about 2.5 months
suggests that a childhood vaccine could be administered fairly soon
after this, assuming minimal matAb interference. However, at least
50% of the population remain seropositive at 4–5 months of age,
and it is plausible that existing Ab titres could interfere with
vaccine response and hence childhood vaccines may not be useful
in this setting, or a schedule with later boosting should be
considered. Delay in the age at vaccine delivery would however
fail to prevent many infections that were observed to occur in this
age group. As high levels of matAb are known to be protective,
maternal vaccination might be another option in this population.
Apart from reducing the potential risk of infection to the mother
and hence the child, a maternal vaccine would potentially boost
matAb levels when transferred to the infant via transplacental
transfer or through breast-feeding, protecting the infant during the
vulnerable period of life when their immune system is still under-
Figure 5. Scatter plot of Ab titres (log10 AU) during the first 6
months of life. The predicted line of fit by simple linear regression:
y=mx+c (rate of decay (slope), m=20.008; intercept, c = 2.928) is
indicated. Only children without serologic evidence of infection during
the first 6 months of life are depicted.
doi:10.1371/journal.pone.0008088.g005
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developed. A clear association between maternally derived RSV
neutralizing antibody titre and RSV seasonality in infants younger
than 6 months of age has recently been described [29]. It thus
remains important that the critical vaccination fraction (those
fractions of each subpopulation that should be vaccinated to
achieve protection against RSV) as well as the recommended age
for vaccination be better established, especially within the
developing country setting.
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